Insulet Co. (NASDAQ:PODD) Shares Purchased by Chicago Capital LLC

Chicago Capital LLC boosted its stake in shares of Insulet Co. (NASDAQ:PODD) by 3.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 168,434 shares of the medical instruments supplier’s stock after buying an additional 5,557 shares during the quarter. Chicago Capital LLC owned 0.24% of Insulet worth $39,203,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in PODD. Raymond James & Associates grew its holdings in shares of Insulet by 3.8% in the 3rd quarter. Raymond James & Associates now owns 37,456 shares of the medical instruments supplier’s stock worth $8,718,000 after acquiring an additional 1,367 shares during the period. Blue Trust Inc. raised its holdings in Insulet by 84.1% during the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 58 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd boosted its position in Insulet by 3.0% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 6,453 shares of the medical instruments supplier’s stock worth $1,502,000 after purchasing an additional 188 shares in the last quarter. Cabot Wealth Management Inc. grew its holdings in Insulet by 1.7% in the third quarter. Cabot Wealth Management Inc. now owns 15,983 shares of the medical instruments supplier’s stock valued at $3,720,000 after purchasing an additional 262 shares during the last quarter. Finally, Swedbank AB increased its position in shares of Insulet by 3.2% in the third quarter. Swedbank AB now owns 21,232 shares of the medical instruments supplier’s stock valued at $4,942,000 after buying an additional 655 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. BTIG Research increased their price objective on shares of Insulet from $250.00 to $260.00 and gave the company a “buy” rating in a research note on Monday, October 14th. UBS Group increased their price target on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research report on Friday, August 9th. Barclays raised their price objective on shares of Insulet from $200.00 to $220.00 and gave the stock an “equal weight” rating in a research note on Monday, August 12th. Piper Sandler upped their target price on Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research note on Tuesday, September 17th. Finally, Raymond James raised their price target on Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a research report on Monday, October 14th. Three investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, Insulet has a consensus rating of “Moderate Buy” and a consensus target price of $242.29.

Insulet Trading Up 3.3 %

NASDAQ PODD opened at $236.59 on Friday. The company has a market cap of $16.59 billion, a P/E ratio of 43.02, a P/E/G ratio of 4.35 and a beta of 1.21. Insulet Co. has a 12 month low of $128.68 and a 12 month high of $243.98. The company has a debt-to-equity ratio of 1.36, a current ratio of 3.60 and a quick ratio of 2.71. The company has a 50-day moving average of $218.20 and a 200-day moving average of $197.05.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 EPS for the quarter, missing the consensus estimate of $0.56 by ($0.01). The company had revenue of $488.50 million for the quarter, compared to analyst estimates of $488.00 million. Insulet had a return on equity of 30.73% and a net margin of 21.11%. The business’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same period last year, the company posted $0.38 EPS. As a group, equities analysts predict that Insulet Co. will post 3.04 earnings per share for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.